Valuation: Nektar Therapeutics

Market Cap 2.58B 2.24B 2.09B 1.91B 3.6B 246B 3.66B 24.49B 9.61B 123B 9.7B 9.49B 407B P/E 2026 *
-8.49x
P/E 2027 * -7.05x
Enterprise Value 2.58B 2.24B 2.09B 1.91B 3.6B 246B 3.66B 24.49B 9.61B 123B 9.7B 9.49B 407B EV / Sales 2026 *
62.3x
EV / Sales 2027 * 69.9x
Free-Float
99.55%
Yield 2026 *
-
Yield 2027 * -
1 day+4.13%
1 week+8.22%
Current month+8.22%
1 month+6.37%
3 months-6.61%
6 months+107.77%
Current year+80.89%
1 week 67.11
Extreme 67.11
77
1 month 64.24
Extreme 64.24
77
Current year 33.4
Extreme 33.4
109
1 year 22.28
Extreme 22.2811
109
3 years 6.19
Extreme 6.188996
109
5 years 6.19
Extreme 6.188996
290.55
10 years 6.19
Extreme 6.188996
1,670.4
Manager TitleAgeSince
Chief Executive Officer 73 2006-12-31
Director of Finance/CFO 60 2026-05-14
Chief Tech/Sci/R&D Officer 52 2015-06-30
Director TitleAgeSince
Director/Board Member 72 2000-07-31
Chairman 69 1992-04-30
Director/Board Member 73 2007-01-31
Date Insider Type Main position Quantity % Market Cap.
7/24/26 Free

Chief Technology Officer

16,500 0.0488%
7/24/26 Free

Chief Executive Officer

57,200 0.1693%
6/30/26 Sell

Chief Technology Officer

-5,681 0.0168%
Change 5-day change 1-year change 3-year change Capi.($)
+4.13%+8.22%+231.66%+409.87% 2.58B
+8.49%+20.55%+70.77%+110.32% 68.12B
+1.25%+2.44%+34.27%+70.43% 55.18B
-1.09%+32.96%+19.67%+494.56% 28.63B
+10.83%+18.38%+56.20%+6.03% 23.99B
+2.72%+3.41%-16.11%-7.96% 23.53B
+6.50%+7.56%+44.65%-21.73% 18.45B
+6.20%+11.51%+33.87%+693.38% 16.44B
-3.88%+16.98%+199.30%+359.77% 15.83B
+3.58%+1.96%+43.35%+163.76% 13.4B
Average +3.87%+11.34%+71.76%+227.84% 26.61B
Weighted average by Cap. +4.35%+13.05%+52.45%+170.82%

Financials

2026 *2027 *
Net sales 41.44M 35.85M 33.48M 30.71M 57.76M 3.94B 58.68M 393M 154M 1.98B 156M 152M 6.54B 36.99M 31.99M 29.88M 27.41M 51.55M 3.52B 52.37M 351M 138M 1.76B 139M 136M 5.83B
Net income -249M -216M -201M -185M -347M -23.71B -353M -2.36B -927M -11.89B -936M -915M -39.29B -351M -303M -283M -260M -489M -33.38B -497M -3.32B -1.3B -16.73B -1.32B -1.29B -55.32B
Net Debt - -
Logo Nektar Therapeutics
Nektar Therapeutics is a clinical-stage biotechnology company. It is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. It is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.
Employees
63
Date Price Change Volume
26-08-07 US$76.48 +4.13% 899,157
26-08-06 US$73.45 +0.49% 403,616
26-08-05 US$73.09 +0.45% 581,029
26-08-04 US$72.76 +3.07% 717,950
26-08-03 US$70.59 -0.11% 611,868
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
76.48USD
Average target price
153.22USD
Spread / Average Target
+100.34%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NKTR Stock